With the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES). In this study, we have stratified HES patients according to their FIP1L1-PDGFRA mutational status and criteria suggestive of a myeloid neoplasm. The peripheral blood and bone marrow specimens were evaluated for dysplastic eosinophils on peripheral smear (abnormal nuclear lobation, uneven granulation, hypogranulation, agranulation), serum B12 level 1000 pg/ml, serum tryptase level 12 ng/mL, anemia and/or thrombocytopenia, bone marrow cellularity >80% with left shift in maturation, dysplastic (spindle-shaped) mast cells on bone marrow biopsy, evidence of reticulin brosis 2+ on bone marrow biopsy, and dysplastic megakaryocytes on bone marrow biopsy. Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with 4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-negative HES with <4 myeloid criteria (SR; n = 5) were enrolled in a prospective study of imatinib therapy. The primary outcome was an eosinophil count <1.5 109/L at one month and improvement of clinical symptoms. Clinical, molecular, and bone marrow responses to imatinib were assessed. In addition, a retrospective cohort of 18 subjects with clinically-defined HES who received imatinib (300-400 mg daily 1 month) were classified according to the criteria used in the prospective study. Overall results showed that imatinib response rates were 100% in the FP group (n = 16), 54% in the MHES group (n = 13) and 0% in the SR group (n = 16). The presence of 4 myeloid features was the sole predictor of response. After 18 months in complete remission, imatinib was tapered and discontinued in 8 FP and 1 MHES subjects. Seven subjects (6 FP, 1 MHES) remained in remission off therapy for a median of 29 months (range 14-36). In conclusion, clinical features of MHES predict imatinib response in PDGFRA-negative HES.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIACL080004-11
Application #
9354087
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
Zip Code
Panch, Sandhya R; Bozik, Michael E; Brown, Thomas et al. (2018) Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood 132:501-509
Prakash Babu, S; Chen, Y-Y K; Bonne-Annee, S et al. (2017) Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy 72:1338-1345
Khoury, P; Desmond, R; Pabon, A et al. (2016) Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy 71:803-10
Khoury, Paneez; Herold, Jacqueline; Alpaugh, Alexandra et al. (2015) Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder. Haematologica 100:300-7
Legrand, Fanny; Tomasevic, Nenad; Simakova, Olga et al. (2014) The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders. J Allergy Clin Immunol 133:1439-47, 1447.e1-8
Klion, Amy D; Mejia, Rojelio; Cowen, Edward W et al. (2013) Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. Blood 121:2364-6
Wilson, Todd M; Maric, Irina; Shukla, Juhi et al. (2011) IL-5 receptor ? levels in patients with marked eosinophilia or mastocytosis. J Allergy Clin Immunol 128:1086-92.e1-3